5/15/2025

Janusmed sex and gender

Janusmed sex and gender – sacubitril valsartan sodium hydrate

Janusmed Sex and Gender is a knowledge database providing information on sex and gender aspects of drug treatment. The knowledge database is primarily intended to be used by physicians and healthcare professionals. The texts are general and should not be considered as treatment guidelines. The individual patient’s physician is responsible for the patient’s drug treatment.

Back to index
A A
A A

Sacubitril + valsartan

Sacubitril + valsartan

Class : A

Show all info

Print

Contact us

  1. Entresto (valsartan/sakubitril). Summary of Product Characteristics. European Medicines Agency (EMA); 2017.

  2. Gan L, Langenickel T, Petruck J, Kode K, Rajman I, Chandra P et al. Effects of age and sex on the pharmacokinetics of LCZ696, an angiotensin receptor neprilysin inhibitor. J Clin Pharmacol. 2016;56:78-86.

  3. Ayalasomayajula S, Langenickel T, Pal P, Boggarapu S, Sunkara G. Clinical Pharmacokinetics of Sacubitril/Valsartan (LCZ696): A Novel Angiotensin Receptor-Neprilysin Inhibitor. Clin Pharmacokinet. 2017;-:[Epub ahead of print].

  4. Food and Drug Aministration (FDA). Clinical Pharmacology and Biopharmaceutics Review - ENTRESTO (sacubitril/valsartan). Food and Drug Administration [www]. [updated 2015-01-27, cited 2017-05-16].

  5. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993-1004.

  6. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2016 [cited 2017-05-20.]

  1. Entresto (valsartan/sakubitril). Summary of Product Characteristics. European Medicines Agency (EMA); 2017.
  2. Gan L, Langenickel T, Petruck J, Kode K, Rajman I, Chandra P et al. Effects of age and sex on the pharmacokinetics of LCZ696, an angiotensin receptor neprilysin inhibitor. J Clin Pharmacol. 2016;56:78-86.
  3. Ayalasomayajula S, Langenickel T, Pal P, Boggarapu S, Sunkara G. Clinical Pharmacokinetics of Sacubitril/Valsartan (LCZ696): A Novel Angiotensin Receptor-Neprilysin Inhibitor. Clin Pharmacokinet. 2017;-:[Epub ahead of print].
  4. Food and Drug Aministration (FDA). Clinical Pharmacology and Biopharmaceutics Review - ENTRESTO (sacubitril/valsartan). Food and Drug Administration [www]. [updated 2015-01-27, cited 2017-05-16].
  5. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993-1004.
  6. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2016 [cited 2017-05-20.]